BACKGROUND: The clinical course of prostate cancer (PCa) measured by biochemical failure (BF) after prostatectomy remains unpredictable in many patients, particularly in intermediate Gleason score (GS) 7 tumors, suggesting that identification of molecular mechanisms associated with aggressive PCa biology may be exploited for improved prognostication or therapy. Hyaluronan (HA) is a high molecular weight polyanionic carbohydrate produced by synthases (HAS1 through HAS3) and fragmented by oxidative/nitrosative stress and hyaluronidases (HYAL1 through HYAL4, SPAM1) common in PCa microenvironments. HA and HA fragments interact with receptors CD44 and hyaluronan-mediated motility receptor (HMMR), resulting in increased tumor aggressiveness in experimental PCa models. This study evaluated the association of HA-related molecules with BF after prostatectomy in GS7 tumors. METHODS: Tissue microarrays were constructed from a 96-patient cohort. HA histochemistry and HAS2, HYAL1, CD44, CD44v6, and HMMR immunohistochemistry were quantified using digital pathology techniques. RESULTS: HA in tumor-associated stroma and HMMR in malignant epithelium were significantly and marginally significantly associated with time to BF in univariate analysis, respectively. After adjusting for clinicopathologic features, both HA in tumor-associated stroma and HMMR in malignant epithelium were significantly associated with time to BF. Although not significantly associated with BF, HAS2 and HYAL1 positively correlated with HMMR in malignant epithelium. Cell culture assays demonstrated that HMMR bound native and fragmented HA, promoted HA uptake, and was required for a promigratory response to fragmented HA. CONCLUSIONS: HA and HMMR are factors associated with time to BF in GS7 tumors, suggesting that increased HA synthesis and fragmentation within the tumor microenvironment stimulates aggressive PCa behavior through HA-HMMR signaling.
BACKGROUND: The clinical course of prostate cancer (PCa) measured by biochemical failure (BF) after prostatectomy remains unpredictable in many patients, particularly in intermediate Gleason score (GS) 7 tumors, suggesting that identification of molecular mechanisms associated with aggressive PCa biology may be exploited for improved prognostication or therapy. Hyaluronan (HA) is a high molecular weight polyanionic carbohydrate produced by synthases (HAS1 through HAS3) and fragmented by oxidative/nitrosative stress and hyaluronidases (HYAL1 through HYAL4, SPAM1) common in PCa microenvironments. HA and HA fragments interact with receptors CD44 and hyaluronan-mediated motility receptor (HMMR), resulting in increased tumor aggressiveness in experimental PCa models. This study evaluated the association of HA-related molecules with BF after prostatectomy in GS7 tumors. METHODS: Tissue microarrays were constructed from a 96-patient cohort. HA histochemistry and HAS2, HYAL1, CD44, CD44v6, and HMMR immunohistochemistry were quantified using digital pathology techniques. RESULTS: HA in tumor-associated stroma and HMMR in malignant epithelium were significantly and marginally significantly associated with time to BF in univariate analysis, respectively. After adjusting for clinicopathologic features, both HA in tumor-associated stroma and HMMR in malignant epithelium were significantly associated with time to BF. Although not significantly associated with BF, HAS2 and HYAL1 positively correlated with HMMR in malignant epithelium. Cell culture assays demonstrated that HMMR bound native and fragmented HA, promoted HA uptake, and was required for a promigratory response to fragmented HA. CONCLUSIONS: HA and HMMR are factors associated with time to BF in GS7 tumors, suggesting that increased HA synthesis and fragmentation within the tumor microenvironment stimulates aggressive PCa behavior through HA-HMMR signaling.
Authors: Mandana Veiseh; Daniel Breadner; Jenny Ma; Natalia Akentieva; Rashmin C Savani; Rene Harrison; David Mikilus; Lisa Collis; Stefan Gustafson; Ting-Yim Lee; James Koropatnick; Leonard G Luyt; Mina J Bissell; Eva A Turley Journal: Biomacromolecules Date: 2011-12-12 Impact factor: 6.988
Authors: Jochen Greiner; Michael Schmitt; Li Li; Krzysztof Giannopoulos; Katrin Bosch; Anita Schmitt; Konstanze Dohner; Richard F Schlenk; Jonathan R Pollack; Hartmut Dohner; Lars Bullinger Journal: Blood Date: 2006-08-24 Impact factor: 22.113
Authors: Alamelu G Bharadwaj; Joy L Kovar; Eileen Loughman; Christian Elowsky; Gregory G Oakley; Melanie A Simpson Journal: Am J Pathol Date: 2009-02-13 Impact factor: 4.307
Authors: Cornelia Tolg; Sara R Hamilton; Ewa Zalinska; Lori McCulloch; Ripal Amin; Natalia Akentieva; Francoise Winnik; Rashmin Savani; Darius J Bagli; Len G Luyt; Mary K Cowman; Jim B McCarthy; Eva A Turley Journal: Am J Pathol Date: 2012-08-11 Impact factor: 4.307
Authors: Kilian M Gust; Matthias D Hofer; Sven R Perner; Robert Kim; Arul M Chinnaiyan; Sooryanarayana Varambally; Peter Moller; Ludwig Rinnab; Mark A Rubin; Jochen Greiner; Michael Schmitt; Rainer Kuefer; Mark Ringhoffer Journal: Neoplasia Date: 2009-09 Impact factor: 5.715
Authors: Chellappagounder Thangavel; Ettickan Boopathi; Yi Liu; Alex Haber; Adam Ertel; Anshul Bhardwaj; Sankar Addya; Noelle Williams; Stephen J Ciment; Paolo Cotzia; Jeffry L Dean; Adam Snook; Chris McNair; Matt Price; James R Hernandez; Shuang G Zhao; Ruth Birbe; James B McCarthy; Eva A Turley; Kenneth J Pienta; Felix Y Feng; Adam P Dicker; Karen E Knudsen; Robert B Den Journal: Cancer Res Date: 2016-12-06 Impact factor: 12.701
Authors: Jeremy Herrera; Colleen Forster; Thomas Pengo; Angeles Montero; Joe Swift; Martin A Schwartz; Craig A Henke; Peter B Bitterman Journal: JCI Insight Date: 2019-01-10
Authors: Davis M Seelig; Daisuke Ito; Colleen L Forster; Una A Yoon; Matthew Breen; Linda J Burns; Veronika Bachanova; Kerstin Lindblad-Toh; Timothy D O'Brien; Stephen C Schmechel; Anthony E Rizzardi; Jaime F Modiano; Michael A Linden Journal: Leuk Lymphoma Date: 2016-12-08
Authors: Veronica R Placencio-Hickok; Marie Lauzon; Natalie Moshayedi; Michelle Guan; Sungjin Kim; Nicholas Nissen; Simon Lo; Stephen Pandol; Brent K Larson; Jun Gong; Andrew E Hendifar; Arsen Osipov Journal: Pancreatology Date: 2021-10-04 Impact factor: 3.996
Authors: Kathryn L Schwertfeger; Mary K Cowman; Patrick G Telmer; Eva A Turley; James B McCarthy Journal: Front Immunol Date: 2015-06-08 Impact factor: 7.561